Idenix Pharmaceuticals (IDIX)

[go seek]

IDX-989 and IDX-899- NNRTIs for HIV

*Better viral resistance profile than efavirenz
– No cross-resistance in highly resistant efavirenz clinical strains
– High barrier to resistance

*No booster needed (potent inhibitor of P450 3A)

*Oral, once-a-day dosing

*No observed adverse events in two animal species at 450 mg/kg/day after two weeks (equivalent to 10g/day in humans)

*Negative genotoxicity

*Exploratory IND filed for both HIV clinical candidates and received go ahead

*Traditional IND will be filed in 1H07 for selected candidate

>>Info from slide 20 (JPM presentation 9 Jan 07)